Abnormal Glomerular Mesangial Cellularity C5539440
A finding indicating abnormal increase in cell density in the supportive tissue of kidney filtering structures. This can signal kidney inflammation or disease and is typically evaluated through kidney biopsy with treatment targeting the specific underlying cause.
Key facts at a glance
- ICD-10
- N28.9
- ICD-11
- GA00.0
- Body system
- renal
- Severity
- moderate
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Warning signs - seek immediate care
Decreased urine output
Reduced frequency or volume of urination indicating impaired kidney filtering.
Seek immediate medical care if urine output drops significantly or stops.
Blood in urine
(renal)Visible pink, red, or brown discoloration of urine due to glomerular bleeding.
Frequency: 70-80% of patients
Foamy urine
(renal)Urine with excessive frothiness indicating significant protein loss in the urine.
Frequency: 65-75% of patients
High blood pressure
(cardiovascular)Elevated blood pressure resulting from kidney fluid and salt retention.
Frequency: 60-70% of patients
Swelling in legs and feet
(constitutional)Fluid accumulation causing puffiness in lower extremities due to reduced kidney function.
Frequency: 50-60% of patients
Fatigue and weakness
(constitutional)Generalized tiredness and reduced energy due to anemia and toxin buildup.
Frequency: 45-55% of patients
Puffiness around eyes
(dermatologic)Swelling in the eyelid area due to protein loss and fluid retention.
Frequency: 40-50% of patients
Nausea and vomiting
(gastrointestinal)Digestive upset due to waste accumulation in the bloodstream from kidney dysfunction.
Frequency: 15-25% of patients
Difficulty concentrating
(neurologic)Cognitive clouding and trouble focusing due to uremic toxin accumulation.
Frequency: 5-10% of patients
Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Immunosuppressive Therapy
Targeted immunosuppressive agents to address underlying immune-mediated mesangial proliferation. Treatment selection depends on biopsy findings and disease severity, with careful consideration of infection risk and other adverse effects.
Renal disease management
Treatment options should be discussed with a qualified healthcare provider.
Corticosteroid Therapy
Short-course or maintenance corticosteroid therapy to reduce mesangial inflammation and cellular proliferation. Dosing and duration depend on disease severity and patient tolerability.
Additional treatment options
Serial Urinalysis and Proteinuria Assessment
Regular urine examination to monitor for hematuria, proteinuria, and cellular casts that correlate with mesangial cellularity changes and treatment response.
monitoringAnti-inflammatory Diet
Dietary modifications emphasizing omega-3 fatty acids, colorful vegetables, and reduced processed food intake to support systemic inflammation reduction and potentially benefit mesangial health.
dietaryStress Management and Support
Psychological support and stress reduction techniques including mindfulness, counseling, and support groups to help cope with chronic illness and potentially reduce inflammation.
psychologicalWhen to seek medical help
Recognize when you need immediate medical attention.
Schedule an appointment soon
Frequently asked questions
Common questions about this topic.
What is Abnormal Glomerular Mesangial Cellularity C5539440?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int. 2021;100(4):S1-S276.
Safirstein B, D'Agati V. Mesangial Biology and the Pathogenesis of IgA Nephropathy. J Am Soc Nephrol. 2020;31(9):1835-1850.
American Society of Nephrology. ASN Guidelines for the Treatment of Glomerular Diseases. Clin J Am Soc Nephrol. 2022;17(1):155-167.
Truong L, Lusco M, Alpers C. Mesangial Hypercellularity in Renal Biopsy Assessment: A Meta-Analysis of Prognostic Value. Kidney Int Rep. 2021;6(4):946-958.
Rovin BH, Barratt J, Batsford PJ, et al. Efficacy and Safety of Nefecon in Patients with Primary IgA Nephropathy (NEFIGAN Trial). Lancet. 2021;397(10269):2073-2084.
Floege J, Alpers CE. The Pathology of Glomerular Diseases. In: Brenner and Rector's The Kidney. 11th ed. Elsevier; 2020:675-748.
International Society of Nephrology. Consensus on Renal Pathology Reporting Standards. Kidney Int. 2019;96(3):522-534.
Said SM, Sethi S, Cornell LD. Mesangial Proliferative Glomerulonephritis: Clinicopathologic Study of 280 Cases. Am J Kidney Dis. 2022;79(2):205-217.
Medication Comparisons
Compare medications used to treat Abnormal Glomerular Mesangial Cellularity C5539440. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy